Altamira Therapeutics Ltd Stock Price, News & Analysis

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has entered a letter of understanding with Wellesta Holdings Pte Ltd for marketing its nasal spray, Bentrio™, in six Asian countries: India, Indonesia, Malaysia, Singapore, Taiwan, and Vietnam. Wellesta will seek registration and distribution of Bentrio™, projected to generate US$5 million to US$10 million in revenues in 2022. This agreement follows similar partnerships in Thailand and the Philippines, expanding Altamira's commercial reach in Southeast Asia.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has announced that the FDA has accepted its 510(k) application for the Bentrio™ nasal spray, aimed at protecting against airborne allergens. This marks a significant milestone towards gaining access to the U.S. market. Following the acceptance, the application is set for a substantive review by the Agency. The company's initiatives focus on RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, with ongoing projects in various developmental phases.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced its participation in A.G.P.'s Virtual Biotech and Specialty Pharma Conference on October 13, 2021. The management will engage in virtual one-on-one investor meetings, although no webcast will be available due to the event's format.

Altamira focuses on unmet medical needs, particularly in RNA therapeutics, allergy protection, and inner ear treatments. Their key products include OligoPhore and SemaPhore (preclinical), Bentrio (commercial), and AM-125 (Phase 2) for vertigo, alongside Keyzilen and Sonsuvi (Phase 3) for tinnitus.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) has provided a business update on Bentrio™, its nasal spray for protection against airborne viruses and allergens. The product launched in Germany and Austria, with plans for expansion into traditional pharmacies. A 510(k) premarket notification for allergy indication has been submitted to the FDA. Recent distributor agreements in Southeast Asia indicate potential for international growth. Clinical studies for allergies and COVID-19 are underway, with results expected in early 2022. CEO Thomas Meyer emphasized the company's transition to a commercial-stage entity.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced a business update regarding its nasal spray, Bentrio™, designed to protect against airborne viruses and allergens. This update will be shared during a live conference call and webcast on September 27, 2021, at 8:00 AM ET. Interested participants can join via phone or online, with an archived version available post-event. Altamira is focused on developing therapies addressing unmet medical needs, including RNA therapeutics and treatments for vertigo and tinnitus.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced that its Chairman and CEO, Thomas Meyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually on September 13-15, 2021. The presentation will be available on demand from 7:00 AM ET on September 13, 2021, via the H.C. Wainwright portal and on Altamira's website under the 'Events and Presentations' section.

Altamira focuses on developing RNA therapeutics, allergy and viral infection protectants, and inner ear therapeutics, with its headquarters in Hamilton, Bermuda.

Altamira Therapeutics (NASDAQ:CYTO) announced the commercial launch of its Bentrio™ nasal spray in select EU markets and outlined its strategic repositioning towards RNA therapeutics following the acquisition of Trasir Therapeutics. The Phase 2 trial for AM-125 for acute vertigo reached enrollment midpoint, with completion expected in Fall 2021. Financially, total operating expenses for H1 2021 rose to CHF 6.5 million, leading to a net loss of CHF 6.8 million, compared to CHF 2.7 million in H1 2020. The company anticipates cash needs between CHF 17.0 to 18.5 million for 2021.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced positive results for its drug-free nasal spray, Bentrio™ (AM-301), showcasing significant effectiveness against influenza A infection. In experiments using human nasal epithelium, Bentrio demonstrated an 84% reduction in viral load when used preventatively and a 77% reduction when administered therapeutically compared to saline controls (p<0.01). Following the success in SARS-CoV-2 trials, these results affirm Bentrio's potential for broad antiviral protection. The nasal spray is set for commercialization in initial European markets.

Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced the launch of a dedicated website for Bentrio™, a drug-free nasal spray aimed at self-protection against airborne viruses and allergens. The product, developed by Altamira Medica, forms a protective gel layer in the nasal cavity, reducing the risk of viral infections and alleviating allergy symptoms. In clinical trials, Bentrio™ demonstrated over 99% reduction in viral load in human cells and significant relief from allergic rhinitis symptoms. The company emphasizes the continued need for protective measures amidst emerging COVID-19 variants.